To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.

United States Government Publishing Office publisher pbl distributor dst United States Congress House of Representatives author aut Government Organization text government publication eng BILLS To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.;Protecting Consumer Access to Generic Drugs Act of 2023;H.R. 6275 (IH) Bills and Statutes 118_cong_bills legislative 2023-11-16 To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes. Protecting Consumer Access to Generic Drugs Act of 2023 H.R. 6275 (IH) U.S. Government Publishing Office 2023-11-07 monographic deposited born digital 20 p. Y 1.6: Y 1.4/6: P0b002ee1c247478f https://www.govinfo.gov/app/details/BILLS-118hr6275ih H.R. 6275 021-610-00252-9 000501532 000325573 Congressional bills House bills f:h6275_ih.txt https://www.govinfo.gov/app/details/BILLS-118hr6275ih https://www.govinfo.gov/content/pkg/BILLS-118hr6275ih/html/BILLS-118hr6275ih.htm https://www.govinfo.gov/content/pkg/BILLS-118hr6275ih/pdf/BILLS-118hr6275ih.pdf https://www.govinfo.gov/content/pkg/BILLS-118hr6275ih/xml/BILLS-118hr6275ih.xml fdlp DGPO 2023-11-16 2023-11-16 BILLS-118hr6275ih machine generated eng Marie Gluesenkamp Perez United States House of Representatives sponsor spn United States Congress Member Sean Casten United States House of Representatives cosponsor United States Congress Member Gerald E. Connolly United States House of Representatives cosponsor United States Congress Member United States Congress House of Representatives Committee on Energy and Commerce associated name asn United States Congress House of Representatives Committee on the Judiciary associated name asn United States Code Title 5 Section 553 5 U.S.C. 553 United States Code Title 15 Section 12(a) Title 15 Section 41et seq. Title 15 Section 45 Title 15 Section 45(a)(1) Title 15 Section 45(a)(2) Title 15 Section 45(g) Title 15 Section 45(g)(1) Title 15 Section 45(l) Title 15 Section 56(a)(2) 15 U.S.C. 12(a) 15 U.S.C. 41et seq. 15 U.S.C. 45 15 U.S.C. 45(a)(1) 15 U.S.C. 45(a)(2) 15 U.S.C. 45(g) 15 U.S.C. 45(g)(1) 15 U.S.C. 45(l) 15 U.S.C. 56(a)(2) United States Code Title 21 Section 321(g) Title 21 Section 355a Title 21 Section 355(b)(1) Title 21 Section 355(b)(2) Title 21 Section 355(c)(3)(E) Title 21 Section 355(j) Title 21 Section 355(j)(5)(B)(iv) Title 21 Section 355(j)(5)(D)(i)(V) Title 21 Section 355(j)(5)(F) Title 21 Section 355(j)(7) Title 21 Section 355note Title 21 Section 355f Title 21 Section 360cc 21 U.S.C. 321(g) 21 U.S.C. 355a 21 U.S.C. 355(b)(1) 21 U.S.C. 355(b)(2) 21 U.S.C. 355(c)(3)(E) 21 U.S.C. 355(j) 21 U.S.C. 355(j)(5)(B)(iv) 21 U.S.C. 355(j)(5)(D)(i)(V) 21 U.S.C. 355(j)(5)(F) 21 U.S.C. 355(j)(7) 21 U.S.C. 355note 21 U.S.C. 355f 21 U.S.C. 360cc United States Code Title 42 Section 262 Title 42 Section 262(a) Title 42 Section 262(i) Title 42 Section 262(k) Title 42 Section 262(k)(6) 42 U.S.C. 262 42 U.S.C. 262(a) 42 U.S.C. 262(i) 42 U.S.C. 262(k) 42 U.S.C. 262(k)(6) United States Statutes at Large Volume 124 Page 817 124 Stat. 817 United States Public Law 148 (111th Congress) Public Law 111-148 hr BILLS-118hr6275ih 118 1 HOUSE HOUSE 6275 ih ih Protecting Consumer Access to Generic Drugs Act of 2023 To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes. Ms. Perez (for herself, Mr. Casten, and Mr. Connolly) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned Committee on Energy and Commerce Energy and Commerce Committee on the Judiciary Judiciary Ms. Perez Marie Gluesenkamp Perez Perez, Marie Gluesenkamp Marie Perez Mr. Casten Sean Casten Casten, Sean Mr. Connolly Gerald E. Connolly Connolly, Gerald E. Mr. Gerald Connolly false false